GlassScriptPhysician profile
Thomas E Puckett
NPI 1346626876
$3,878.68
in general payments reported to CMS, 2019-2025
20 companies · $636 in 2025
The $636 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $755 · 2022: $1,030 · 2023: $1,040 · 2024: $419 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $649.60 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $557.09 | 2021-2024 | Lokelma, Breztri, Farxiga |
| Acadia Pharmaceuticals INC | $466.58 | 2023-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $350.47 | 2022-2024 | Ingrezza |
| Sumitomo Pharma America, INC. | $265.20 | 2023 | Aptiom, Gemtesa |
| Sun Pharmaceutical Industries INC. | $251.90 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $216.49 | 2023 | Rexulti, Jynarque |
| Abbvie INC. | $125.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $124.26 | 2025 | |
| Amgen INC. | $119.62 | 2025 | Krystexxa |
| Alpha Cognition USA, INC. | $112.15 | 2025 | Zunveyl |
| Takeda Pharmaceuticals U.S.A., INC. | $99.54 | 2022 | |
| Janssen Pharmaceuticals, INC | $99.19 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.96 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.31 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $86.94 | 2021 | |
| Avanir Pharmaceuticals, INC. | $67.62 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.02 | 2021 | |
| Jazz Pharmaceuticals INC. | $27.50 | 2025 | |
| Mylan Specialty L.P. | $20.24 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Puckett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.